When you read a peptide certificate of analysis (COA), the reported purity figure describes the peptide salt, not the pure peptide chain itself. The counter-ion — the charged molecule that pairs with the peptide during manufacturing — makes up part of that mass, and its identity matters when comparing products or interpreting net peptide content.
What is a salt form?
Peptides are synthesized as charged molecules. During and after solid-phase peptide synthesis (SPPS), the free amino and guanidinium groups on the peptide backbone carry positive charges that must be balanced by a negatively charged counter-ion. The resulting compound is a peptide salt: the peptide itself paired with an anionic species. The two counter-ions encountered most often in research-grade peptides are acetate (CH₃COO⁻) and trifluoroacetate (CF₃COO⁻, commonly abbreviated TFA).
The salt form does not change the peptide's amino acid sequence or its primary structure. What it does change is the molecular weight of the compound as-weighed, and therefore the actual moles of peptide present in a given mass of product.
Acetate vs. trifluoroacetate
TFA enters the product during the cleavage and deprotection step of SPPS. Trifluoroacetic acid is used in large excess to remove protecting groups from the assembled chain, and residual TFA ions bind tightly to the peptide's basic sites. Because TFA has a molecular weight of approximately 113 g/mol — substantially heavier than acetate at roughly 59 g/mol — a higher proportion of the weighed mass is counter-ion rather than peptide. For longer or more basic peptides (those with multiple lysine, arginine, or histidine residues), TFA content can account for a meaningful fraction of total mass.
Acetate counter-ions are introduced by washing or exchanging the crude peptide with acetic acid or ammonium acetate buffers after purification. Acetate salts are lighter and are generally considered more suitable for biological assay work, partly because TFA has been reported in the research literature to have cytotoxic effects at higher concentrations in cell-based experiments.
| Property | Acetate form | TFA form |
|---|---|---|
| Counter-ion formula | CH₃COO⁻ | CF₃COO⁻ |
| Approximate MW of counter-ion | ~59 g/mol | ~113 g/mol |
| Introduced by | Post-purification ion exchange | SPPS deprotection step |
| Net peptide content (relative) | Higher per gram weighed | Lower per gram weighed |
| Common concern in research | Generally less noted | Reported cytotoxicity in cell assays |
Why net peptide content matters
A COA reporting "98% purity by HPLC" describes the ratio of the target peptide peak to all other peaks in the chromatogram. Counter-ions such as TFA and acetate are UV-transparent at the wavelengths typically used for peptide analysis (214–220 nm) and do not register as peaks — meaning HPLC purity provides no information about their presence or mass fraction. Two products with identical HPLC purity can therefore deliver different moles of active peptide per milligram if one is the acetate salt and the other is the TFA salt. Some vendors and independent testing labs (including Janoshik and Peptigrity) separately report net peptide content — a quantitative figure, typically determined by nitrogen analysis or amino acid analysis, that reflects the actual peptide mass fraction after accounting for counter-ions, water, and residual solvents. Research-oriented buyers often look for this figure alongside HPLC purity because it provides a more complete picture of what is in the vial.
Pharmacopeial monographs and guidance documents from bodies such as the USP and the European Medicines Agency describe net peptide content testing methods for approved peptide drug substances. For research-grade peptides sold outside any regulatory approval framework — which describes the overwhelming majority of peptides available through online vendors — independent third-party COAs remain the primary mechanism by which buyers can assess salt form and net content.